BG103930A - Eletriptan hemisulphate and caffeine containing pharmaceutical compositions - Google Patents

Eletriptan hemisulphate and caffeine containing pharmaceutical compositions

Info

Publication number
BG103930A
BG103930A BG103930A BG10393099A BG103930A BG 103930 A BG103930 A BG 103930A BG 103930 A BG103930 A BG 103930A BG 10393099 A BG10393099 A BG 10393099A BG 103930 A BG103930 A BG 103930A
Authority
BG
Bulgaria
Prior art keywords
pharmaceutical compositions
containing pharmaceutical
eletriptan hemisulphate
caffeine containing
caffeine
Prior art date
Application number
BG103930A
Other languages
Bulgarian (bg)
English (en)
Inventor
Valerie Harding
Anne Billotte
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103930A publication Critical patent/BG103930A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG103930A 1997-07-03 1999-11-30 Eletriptan hemisulphate and caffeine containing pharmaceutical compositions BG103930A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions
PCT/EP1998/004176 WO1999001135A1 (en) 1997-07-03 1998-07-01 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Publications (1)

Publication Number Publication Date
BG103930A true BG103930A (en) 2000-07-31

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103930A BG103930A (en) 1997-07-03 1999-11-30 Eletriptan hemisulphate and caffeine containing pharmaceutical compositions

Country Status (31)

Country Link
US (1) US6166025A (ja)
EP (1) EP0999841B1 (ja)
JP (1) JP3350061B2 (ja)
CN (1) CN1145486C (ja)
AT (1) ATE206921T1 (ja)
AU (1) AU724728B2 (ja)
BG (1) BG103930A (ja)
BR (1) BR9810658A (ja)
CA (1) CA2292673C (ja)
DE (1) DE69802097T2 (ja)
DK (1) DK0999841T3 (ja)
DZ (1) DZ2549A1 (ja)
EA (1) EA002174B1 (ja)
ES (1) ES2163291T3 (ja)
HK (1) HK1029282A1 (ja)
HR (1) HRP990416B1 (ja)
HU (1) HUP0004468A3 (ja)
ID (1) ID24528A (ja)
IL (1) IL133206A0 (ja)
IS (1) IS5283A (ja)
MA (1) MA26518A1 (ja)
NO (1) NO312993B1 (ja)
NZ (1) NZ501419A (ja)
OA (1) OA11227A (ja)
PL (1) PL337803A1 (ja)
PT (1) PT999841E (ja)
SI (1) SI0999841T1 (ja)
SK (1) SK284462B6 (ja)
TR (1) TR199903332T2 (ja)
UY (1) UY25078A1 (ja)
WO (1) WO1999001135A1 (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
AU4799700A (en) 1999-04-27 2000-11-10 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
CN101076325A (zh) * 2004-10-22 2007-11-21 萧兴仁 含可食用羧酸和/或其酸性盐与咖啡碱的药物组合物以及无毒瘾性咖啡
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070111964A1 (en) 2005-08-17 2007-05-17 Fleming And Company, Pharmaceuticals Vitamin B12 nasal spray and method of use
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP5776355B2 (ja) * 2010-07-16 2015-09-09 大正製薬株式会社 内服液剤
US8915245B2 (en) 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
WO2014143453A1 (en) * 2013-03-15 2014-09-18 Henkin Robert I Phosphodiesterase inhibitor treatment
EP3488889A1 (en) 2013-08-08 2019-05-29 Vapotherm, Inc. Respiratory therapy condensation adaptor
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
BR9810658A (pt) 2000-10-03
SK284462B6 (sk) 2005-04-01
DE69802097D1 (de) 2001-11-22
CN1145486C (zh) 2004-04-14
CN1261279A (zh) 2000-07-26
AU8856998A (en) 1999-01-25
EP0999841B1 (en) 2001-10-17
NO312993B1 (no) 2002-07-29
CA2292673A1 (en) 1999-01-14
IL133206A0 (en) 2001-03-19
HUP0004468A2 (hu) 2001-10-28
NO995887L (no) 2000-03-02
HK1029282A1 (en) 2001-03-30
ES2163291T3 (es) 2002-01-16
EA002174B1 (ru) 2002-02-28
EP0999841A1 (en) 2000-05-17
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
TR199903332T2 (xx) 2000-09-21
DK0999841T3 (da) 2001-11-19
HRP990416A2 (en) 2000-04-30
WO1999001135A1 (en) 1999-01-14
AU724728B2 (en) 2000-09-28
SI0999841T1 (ja) 2001-12-31
NZ501419A (en) 2000-09-29
DZ2549A1 (fr) 2003-02-08
HUP0004468A3 (en) 2004-07-28
UY25078A1 (es) 2000-12-29
HRP990416B1 (en) 2002-04-30
PL337803A1 (en) 2000-09-11
JP3350061B2 (ja) 2002-11-25
EA199901100A1 (ru) 2000-08-28
DE69802097T2 (de) 2002-03-14
ATE206921T1 (de) 2001-11-15
SK182899A3 (en) 2000-09-12
PT999841E (pt) 2002-02-28
CA2292673C (en) 2003-04-22
OA11227A (en) 2003-07-18
IS5283A (is) 1999-11-30
ID24528A (id) 2000-07-20
US6166025A (en) 2000-12-26
JP2000516262A (ja) 2000-12-05

Similar Documents

Publication Publication Date Title
BG103930A (en) Eletriptan hemisulphate and caffeine containing pharmaceutical compositions
AP9901534A0 (en) Pharmaceutical formulations.
HUP9903174A2 (hu) Koenzim Q-10-et tartalmazó gyógyászati készítmény
MY118151A (en) Pharmaceutical formulations containing voriconazole.
MY134559A (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
BG102172A (en) New stable medicamentous compositions for the preparation of propellant-free aerosols
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
CA2348086A1 (en) Controlled-release pharmaceutical formulations
IL133397A (en) Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
CA2270177A1 (en) Transdermal administration of ment
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
ZA961138B (en) Solid active ingredient compositions containing hydroxypropylcellulose.
CA2152771A1 (en) 7-o-ethers of taxane derivatives
WO1999006388A8 (en) Pharmaceutical compounds isolated from aristolochia taliscana
CA2284142A1 (en) Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG103306A (en) Liquid allendronate compositions
BG106151A (en) Pharmaceutical complex
TW218011B (ja)
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
BG102638A (en) Tablets having increased phamcyclovir content
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.